SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 7.38 |
| Enterprise Value ($M) | -9.82 |
| Book Value ($M) | -11.12 |
| Book Value / Share | -0.41 |
| Price / Book | -0.66 |
| NCAV ($M) | -32.19 |
| NCAV / Share | -1.20 |
| Price / NCAV | -0.23 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.99 |
| Return on Assets (ROA) | -0.66 |
| Return on Equity (ROE) | -2.69 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.25 |
| Current Ratio | 2.25 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 63.93 |
| Assets | 85.00 |
| Liabilities | 96.12 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Blue Owl Capital Holdings LP | 1.92 | -65.45 | |
| 13G/A | Bain Capital Life Sciences Fund II, L.P. | 9.99 | 0.01 | |
| 13G/A | Avidity Partners Management LP | 9.90 | 7.34 | |
| 13G/A | Invus Global Management, LLC | 9.90 | 2.31 | |
| 13G/A | Ally Bridge MedAlpha Master Fund L.P. | 2.60 | -60.33 | |
| 13G/A | Artal International S.C.A. | 9.90 | 143.80 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 9.99 | 109.28 | |
| 13G | Point72 Asset Management, L.P. | 5.70 | ||
| 13D/A | Samsara BioCapital, L.P. | 9.50 | 56.68 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,401,733 | 5,015,948 | 27.95 | |
| 4,891,110 | 14,547,675 | 33.62 | |
| 6,589,581 | 24,103,098 | 27.34 | |
| 116,930 | 515,954 | 22.66 | |
| 307,045 | 1,011,752 | 30.35 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SVRA – Savara Inc. | SWTX – SpringWorks Therapeutics, Inc. |
| SYRE – Spyre Therapeutics, Inc. | TARS – Tarsus Pharmaceuticals, Inc. |
| TECH – Bio-Techne Corporation |
Financial data and stock pages provided by
Fintel.io